Search results

Skip to results

Type

Type

Last updated

Last updated

Advice programme

Showing 1 result for amikacin liposomal

  1. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Evidence summary
    Published
    12 May 2021